ProMIS Neurosciences (PMN) has provided an announcement.
ProMIS Neurosciences Inc. announced findings from a recent study suggesting that the effectiveness of amyloid-beta-directed antibodies in treating Alzheimer’s disease could be linked to their ability to target toxic soluble aggregates. The company’s lead product, PMN310, demonstrated a promising degree of selectivity and resistance to common issues in clinical studies. With Phase 1a trials underway and results expected mid-2024, PMN310 shows potential for reducing complications such as brain edema and microhemorrhages associated with other treatments. This breakthrough could signal a significant advancement in Alzheimer’s therapies, with plans for further clinical development.
Find detailed analytics on PMN stock on TipRanks’ Stock Analysis page.